Cargando…

Occurrence of comorbid diseases in patients after COVID-19

The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamilova, Umida, Ermekbaeva, Akbal, Nuritdinov, Nuriddin, Khamraev, Abror, Zakirova, Gulnoza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165508/
https://www.ncbi.nlm.nih.gov/pubmed/37168295
http://dx.doi.org/10.25122/jml-2022-0168
_version_ 1785038278640009216
author Kamilova, Umida
Ermekbaeva, Akbal
Nuritdinov, Nuriddin
Khamraev, Abror
Zakirova, Gulnoza
author_facet Kamilova, Umida
Ermekbaeva, Akbal
Nuritdinov, Nuriddin
Khamraev, Abror
Zakirova, Gulnoza
author_sort Kamilova, Umida
collection PubMed
description The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes.
format Online
Article
Text
id pubmed-10165508
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-101655082023-05-09 Occurrence of comorbid diseases in patients after COVID-19 Kamilova, Umida Ermekbaeva, Akbal Nuritdinov, Nuriddin Khamraev, Abror Zakirova, Gulnoza J Med Life Original Article The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes. Carol Davila University Press 2023-03 /pmc/articles/PMC10165508/ /pubmed/37168295 http://dx.doi.org/10.25122/jml-2022-0168 Text en ©2023 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Kamilova, Umida
Ermekbaeva, Akbal
Nuritdinov, Nuriddin
Khamraev, Abror
Zakirova, Gulnoza
Occurrence of comorbid diseases in patients after COVID-19
title Occurrence of comorbid diseases in patients after COVID-19
title_full Occurrence of comorbid diseases in patients after COVID-19
title_fullStr Occurrence of comorbid diseases in patients after COVID-19
title_full_unstemmed Occurrence of comorbid diseases in patients after COVID-19
title_short Occurrence of comorbid diseases in patients after COVID-19
title_sort occurrence of comorbid diseases in patients after covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165508/
https://www.ncbi.nlm.nih.gov/pubmed/37168295
http://dx.doi.org/10.25122/jml-2022-0168
work_keys_str_mv AT kamilovaumida occurrenceofcomorbiddiseasesinpatientsaftercovid19
AT ermekbaevaakbal occurrenceofcomorbiddiseasesinpatientsaftercovid19
AT nuritdinovnuriddin occurrenceofcomorbiddiseasesinpatientsaftercovid19
AT khamraevabror occurrenceofcomorbiddiseasesinpatientsaftercovid19
AT zakirovagulnoza occurrenceofcomorbiddiseasesinpatientsaftercovid19